Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | NT5E | P21589 | 7/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644803 | 0.90 | NT5E (0.40) | CA12CA1CA2CA9NT5E | |
| SCHEMBL18067110 | 0.90 | NT5E (0.40) | CA12CA1CA2CA9NT5E | |
| SCHEMBL22224830 | 0.89 | ADORA3 (0.40) | CA12CA1CA2CA9NT5E | |
| SCHEMBL20977483 | 0.86 | NT5E (0.43) | NT5E | |
| SCHEMBL12150418 | 0.86 | NT5E (0.43) | NT5E | |
| SCHEMBL21136511 | 0.84 | CA5A (0.44) | NT5EP2RY1 | |
| SCHEMBL18061705 | 0.83 | CA12 (0.39) | CA12CA1CA2CA9NT5E | |
| SCHEMBL12831829 | 0.82 | NT5E (0.40) | NT5E | |
| SCHEMBL21136510 | 0.82 | P2RY1 (0.45) | NT5EP2RY1P2RY12ENPP1 | |
| SCHEMBL21136278 | 0.81 | P2RX3 (0.46) | NT5EP2RY1P2RY12ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Atea Pharmaceuticals, Inc. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CA12 4837/4885CA1 4883/4885CA2 4845/4885 |
| US-10946033-B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | NSUN2, ADAR, NSUN3 | CA12 4853/4885CA1 4883/4885CA2 4849/4885 |
| US-20190201433-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CA12 4837/4885CA1 4883/4885CA2 4845/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | CA12 4837/4885CA1 4883/4885CA2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.